Next-Generation Recombinant Vaccines for Veterinary Infectious Diseases
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Veterinary Vaccines".
Deadline for manuscript submissions: 15 April 2027 | Viewed by 209
Special Issue Editors
Interests: recombinant vaccines; mRNA vaccines; emerging and re-emerging viruses; one health
Special Issues, Collections and Topics in MDPI journals
Interests: Zika; encephalitis virus; virus-like particles; genetic engineering of baculoviruses; recombinant vaccines against viruses; viral biopesticides; SARS-CoV-2; influenza virus
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Recombinant vaccines have transformed veterinary medicine by enabling precise delivery of pathogen-specific antigens through advanced genetic and protein engineering technologies. Platforms such as viral vectors, subunit vaccines, DNA vaccines, and emerging mRNA-based systems, along with nanoparticle antigen display, offer enhanced safety, immunogenicity, and DIVA compatibility. These approaches are increasingly applied to control economically significant and zoonotic diseases in livestock, poultry, and companion animals. Despite substantial progress, challenges remain in delivery optimization, cost-effectiveness, and achieving consistent immune responses across species. Continued innovation in recombinant and mRNA vaccine design is required for improving global animal health, productivity, and food security. We welcome submissions of original research articles, reviews, and perspectives related to (but not limited to) this Special Issue.
Dr. Ravendra P. Chauhan
Prof. Dr. Boguslaw Szewczyk
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- veterinary
- recombinant vaccines
- viral vectors
- mRNA vaccine
- subunit vaccines
- vaccine platforms
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
